This article is more than 5 years old. Information may no longer be current.

IND application accepted for Aerie's AR-1105

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted an investigational new drug application for AR-1105, a treatment candidate for macular edema due to retinal vein occlusion, Aerie Pharmaceuticals announced in a press release.

AR-1105 (dexamethasone intravitreal implant) is a bioerodible implant designed to release the steroid over a 6-month period.

Aerie plans to begin a phase 2 clinical study later in the first quarter, the release said.

“This quarter we also plan to file an IND for our second retina product, a bioerodible implant containing the Rho kinase/protein kinase C inhibitor AR-13503 that is being developed for wet age-related macular degeneration and diabetic macular edema,” Aerie Chairman and CEO Vicente Anido Jr., PhD, said in the release.